Table 2

Cancer treatment details

Patient	Stage	Grade	Cancer	Radiotherapy	Other treatments
1	T3A N0 M0	No biopsy	Prostate	60 Gy/20#	6 months bicalutamide
2	T2c N0 M0	Gleason 3+3	Prostate	60 Gy/20#	Nil
3	T2 N0 M0	Gleason 3+4	Prostate	60 Gy/20#	6 months LHRH antagonist
4	T2b N0 M0	Gleason 4+3	Prostate	60 Gy/20#	7 months LHRH antagonist
5	T2 N0 M0	Grade 2	Rectal	NK	Perianal resection of rectal lesion
6	T1c N0 M0	Gleason 3+3	Prostate	57 Gy/19#	3 months LHRH antagonist
7	Stage 1B with positive margins and lymphovascular invasion	Grade 3	Vaginal	45 Gy/25#	2 x HDR brachytherapy
8	T1c N0 M0	Gleason 3+4	Prostate	60 Gy/20#	6 months LHRH antagonist
9	TXN0	Grade 2	Rectal	25 Gy/5#	Papillon topical radiotherapy
10	T2b N0 M0	Gleason 3+4	Prostate	60 Gy/20#	7 months LHRH antagonist
11	Stage 2	Grade 3	Vaginal	60 Gy/30#	Cisplatin x2 Early cessation due to toxicity
12	NK	NK	NK	NK	NK
13	T2a N0 M0	Gleason 4+5	Prostate	60 Gy/20#	25 months LHRH antagonist
14	T2c N0 M0	Gleason 3+3	Prostate	72 Gy/32#	6 months LHRH antagonist
15	T1c N0 M0	Gleason 3+4	Prostate	60 Gy/20#	Nil
16	T4 N0 M0	Gleason 3+3	Prostate	50 Gy/16#	Six cycles Docetaxel chemo pre-XRT in STAMPEDE trial 15 months LHRH antagonist
17	T2 N0 Mx	Gleason 3+4	Prostate	NK	LHRH antagonist
18	T3b N0 M0	Gleason 4+3 +5	Prostate	52.5 Gy/20# Prostate bed	Radical prostatectomy
19	T3a N0 M0	Gleason 4+3	Prostate	60 Gy/20#	3 months LHRH antagonist
20	T2c N0 M0	Gleason 3+4	Prostate	60 Gy/20#	Nil
21	T2 N0 M0	Gleason 4+5	Prostate	60 Gy/20#	6 months LHRH antagonist

Data not obtainable from treating sites.
.HDR, High dose-rate brachytherapy; LHRH, Luteinising hormone-releasing hormone; NK, not known; ; STAMPEDE, Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy; XRT, Radiotherapy.